40 Hz Ultrasound for Health & Longevity

Evidence Review created on 04/24/2026 using AI4L / Opus 4.7

Also known as: 40 Hz Transcranial Ultrasound Stimulation, 40 Hz TUS, Gamma-Frequency Ultrasound, 40 Hz Transcranial Focused Ultrasound, Gamma Entrainment Using Ultrasound

Motivation

40 Hz ultrasound is a non-invasive brain stimulation technique that delivers focused ultrasonic pressure waves pulsed at the gamma rhythm associated with attention, memory, and coordinated communication between brain regions. Unlike light- or sound-based gamma stimulation, ultrasound can pass through the skull and reach deep structures such as the hippocampus, giving it a unique profile among emerging neuromodulation tools.

Interest grew from the observation that gamma activity is reduced in Alzheimer’s disease and in normal aging, often long before symptoms appear. Preclinical work showing that 40 Hz stimulation can reduce amyloid-beta plaques, activate the brain’s waste-clearance system, and preserve white matter has drawn attention from the longevity community, and parallel audiovisual 40 Hz work has produced the first suggestive human data on brain atrophy and cognition.

This review examines the current state of evidence for 40 Hz ultrasound specifically, draws on the broader gamma entrainment literature where it informs expectations, and clarifies what is known, what is plausible, and what remains unproven for individuals oriented toward long-term brain health.

Benefits - Risks - Protocol - Conclusion

Grokipedia

No dedicated Grokipedia article for 40 Hz Ultrasound exists as of April 2026.

Examine

No dedicated Examine article for 40 Hz Ultrasound exists as of April 2026.

ConsumerLab

No dedicated ConsumerLab article for 40 Hz Ultrasound exists as of April 2026.

Systematic Reviews

A selection of systematic reviews and meta-analyses relevant to 40 Hz ultrasound and the broader fields of transcranial ultrasound stimulation and 40 Hz gamma entrainment.

The Effectiveness and Safety of Low-Intensity Transcranial Ultrasound Stimulation: A Systematic Review of Human and Animal Studies - Qin et al., 2024

Systematic review of eleven human and forty-four animal studies of low-intensity transcranial ultrasound stimulation reporting therapeutic efficacy signals in neurological disorders, psychiatric conditions, pain, and sleep disorders, with no adverse effects in controlled animal studies and only transient, reversible headache, nausea, and vomiting in a small minority of human subjects.
Transcranial Ultrasound Stimulation Parameters for Neurological Diseases: A Systematic Review - Wang et al., 2025

Systematic review of thirty-five human studies including ten RCTs (randomized controlled trials, studies where participants are assigned at random to treatment or control to reduce bias) examining how transcranial ultrasound stimulation parameters modulate brain function, finding that carrier frequency, pulse repetition frequency, and mechanical index materially influence outcomes, with transient adverse effects in under five percent of participants.
Safety of Transcranial Focused Ultrasound Stimulation: A Systematic Review of the State of Knowledge from Both Human and Animal Studies - Pasquinelli et al., 2019

Systematic review of thirty-three studies evaluating safety of transcranial focused ultrasound, finding adverse effects rare overall, with microhemorrhages reported only in studies that intentionally exceeded safety limits, and a generally favorable safety profile even when FDA (Food and Drug Administration, the U.S. agency that regulates medical devices and drugs) safety indices were partially exceeded.

Mechanism of Action

40 Hz ultrasound acts through several complementary mechanisms, combining the general effects of low-intensity transcranial ultrasound with the specific neural consequences of stimulating at gamma frequency.

Mechanotransduction: Ultrasound is a mechanical pressure wave. When pulsed at 40 Hz, it activates mechanosensitive ion channels in neurons, particularly Piezo1 (a stretch-activated ion channel that converts mechanical force into electrical signals) and voltage-gated potassium, sodium, and calcium channels. The resulting shifts in membrane potential increase neural excitability and allow the ultrasound to drive synchronous firing at gamma frequency.
Gamma oscillation entrainment: The 40 Hz pulse repetition frequency paces large populations of neurons to fire together at gamma frequency. This restores the gamma power and cross-regional phase coherence that are reduced in Alzheimer’s disease and aging. Theta-gamma phase-amplitude coupling (the coordination of slow and fast brain rhythms that supports memory) and hippocampal sharp-wave ripples are enhanced after stimulation.
Microglial activation and phenotype shift: 40 Hz activity shifts microglia (the brain’s resident immune cells) from a pro-inflammatory toward a phagocytic, clearance-oriented phenotype. Activated microglia cluster around amyloid plaques and increase their uptake of amyloid-beta, the protein fragment that aggregates into these plaques.
Glymphatic clearance: 40 Hz stimulation promotes cerebrospinal fluid influx and interstitial fluid efflux through the glymphatic system (the brain’s waste-clearance network that operates primarily during sleep). VIP (vasoactive intestinal peptide, a neuropeptide released by a specific interneuron class) interneurons regulate arterial pulsatility, which drives fluid flow. Increased polarization of aquaporin-4 (a water channel protein on astrocytic endfeet that channels fluid into and out of brain tissue) further supports clearance.
Deep brain access: Unlike light or audible sound, focused ultrasound crosses the skull and can reach the hippocampus, thalamus, and basal ganglia with millimeter-scale focal precision. This allows direct stimulation of regions most affected in Alzheimer’s disease and related dementias that cannot be targeted by sensory stimulation alone.

Because 40 Hz ultrasound is a physical stimulus rather than a pharmacological compound, classical pharmacological properties such as half-life, tissue distribution, and metabolism do not apply. The closest analogues are the acoustic dose (intensity and exposure time) and the duration of neural after-effects, which have been documented to persist for days after a single session in preclinical work.

Historical Context & Evolution

The idea of using 40 Hz stimulation to protect the brain emerged from two converging research lines. Gamma oscillations were first identified in the mid-twentieth century, but their functional significance was not appreciated until the late 1980s and 1990s, when researchers linked gamma activity to attention, perceptual binding, and working memory. By the early 2000s, investigators had established that gamma power is reduced in Alzheimer’s disease and in animal models of the disease, correlating with the degree of cognitive decline.

The pivotal modern chapter began in 2016 at the Picower Institute at MIT, when Li-Huei Tsai and colleagues reported that exposing Alzheimer’s model mice to 40 Hz flickering light cut amyloid-beta plaques in the visual cortex roughly in half after one hour of stimulation. Subsequent work expanded the method to combined audiovisual stimulation, documented effects across additional brain regions, and demonstrated cognitive improvements. In 2024, the same group published a widely cited paper in Nature identifying glymphatic clearance, driven by VIP-interneuron-mediated arterial pulsation, as a core mechanism by which 40 Hz stimulation removes amyloid from the brain.

The ultrasound branch opened in 2020 and 2021, when Park and colleagues at the Gwangju Institute of Science and Technology showed that transcranial ultrasound pulsed at 40 Hz could achieve gamma entrainment in Alzheimer’s model mice without relying on sensory pathways. This was an important step because it meant that gamma-frequency stimulation could be delivered without prolonged flickering light and could be aimed directly at deep structures such as the hippocampus, which sensory stimulation reaches only indirectly. A wider TUS (transcranial ultrasound stimulation, a non-invasive neuromodulation technique using focused ultrasonic pressure waves to activate or suppress neural activity) literature had already been accumulating safety and feasibility data across indications including depression, chronic pain, and disorders of consciousness.

Clinical translation of 40 Hz gamma entrainment has been led largely by Cognito Therapeutics, a Picower Institute spinoff, whose OVERTURE phase II trial used audiovisual gamma stimulation in mild-to-moderate Alzheimer’s disease. It is worth noting that Cognito Therapeutics has a direct financial interest in the success of 40 Hz gamma stimulation as a therapy, and this interest should be kept in mind when interpreting trial design choices, primary endpoint selection, and emphasis in the resulting publications. 40 Hz TUS-specific human studies are still at an early stage as of 2026, although multiple ultrasound trials for neurodegenerative disease, depression, and cognitive enhancement are recruiting. The field continues to evolve, and current framings of which modality, region, and parameters are optimal should be treated as provisional rather than settled.

Expected Benefits

A dedicated search of the complete benefit profile of 40 Hz ultrasound was performed across PubMed, institutional research summaries, and expert commentary before writing this section.

Medium 🟩 🟩

Amyloid-Beta Plaque Reduction

Preclinical studies consistently show that 40 Hz ultrasound reduces amyloid-beta burden in Alzheimer’s model mice. Park and colleagues reported reductions of insoluble amyloid-beta-42 and plaque counts in the cortex and hippocampus after roughly two weeks of daily stimulation. Subsequent studies combining 40 Hz ultrasound with 40 Hz light have reported additional reductions compared to either modality alone. Human data specific to 40 Hz TUS are not yet available; the closest human signal comes from the audiovisual OVERTURE trial, which showed reduced brain atrophy as an indirect marker.

Magnitude: Approximately 50% reduction in amyloid-beta plaque load in preclinical models after two weeks of daily treatment; human translation pending.

Improved Memory and Cognitive Function

Behavioral improvements have been reported in Alzheimer’s model mice treated with 40 Hz TUS, including better performance on spatial memory and novel object recognition tasks, with effects persisting for several days after stimulation ended. In the human OVERTURE trial of audiovisual 40 Hz stimulation, cognitive screening scores showed a modest advantage favoring active treatment over six months, though not all primary cognitive endpoints reached statistical significance.

Magnitude: Statistically significant improvements on spatial memory tasks in preclinical models; approximately one-point advantage on cognitive screening scores in the audiovisual OVERTURE trial over six months; no direct human 40 Hz TUS cognitive data.

Reduced Brain Atrophy and White Matter Preservation

The OVERTURE trial of audiovisual 40 Hz stimulation reported a statistically significant reduction in whole-brain volume loss versus sham over six months, with preservation of white matter volume and corpus callosum structure. If 40 Hz TUS recruits the same glymphatic and microglial mechanisms identified in preclinical models, similar structural effects are plausible but not yet demonstrated in humans.

Magnitude: Approximately a two-percentage-point between-group difference in corpus callosum area change over six months in the audiovisual OVERTURE trial; structural effects of TUS specifically not yet quantified in humans.

Low 🟩

Enhanced Gamma Power and Neural Synchrony

40 Hz TUS increases spontaneous gamma power and normalizes cross-frequency coupling between theta and gamma rhythms in preclinical models, and acute human TUS studies at other parameters confirm that ultrasound can modulate oscillatory activity. Improved neural synchrony is considered a functional marker of healthier brain network communication and has been proposed as a biomarker for treatment engagement.

Magnitude: Significant increases in gamma-band power and phase-amplitude coupling in preclinical models, with enhanced coupling persisting for at least five days after stimulation; human quantitative data limited.

Microglial Activation and Neuroinflammation Modulation

40 Hz ultrasound activates microglia toward a phagocytic, neuroprotective phenotype in preclinical models, with altered morphology consistent with a shift from surveillance to active clearance. This effect has been replicated across different 40 Hz modalities, suggesting it is driven primarily by the gamma frequency rather than by the specific stimulation channel.

Magnitude: Not quantified in available studies.

Glymphatic Clearance Enhancement

Through VIP-interneuron-mediated arterial pulsatility and increased aquaporin-4 polarization, 40 Hz stimulation promotes glymphatic removal of metabolic waste. Inhibiting glymphatic clearance abolishes the amyloid-reducing effect of 40 Hz stimulation in preclinical models, establishing this pathway as central rather than incidental.

Magnitude: Not quantified in available studies.

Speculative 🟨

Gamma oscillation deficits are detectable years before clinical Alzheimer’s disease, and the mechanisms engaged by 40 Hz stimulation (glymphatic clearance, microglial phenotype, white matter preservation) are relevant to normal aging rather than specific to amyloid pathology. Prophylactic use in cognitively healthy adults has been proposed as a natural extension of this reasoning but has not been directly tested in randomized trials.

Mood and Sleep Improvement

The audiovisual OVERTURE trial reported reductions in sleep fragmentation and longer deep sleep, and other low-intensity TUS studies targeting the thalamus and prefrontal cortex have suggested anxiolytic and mood effects. Whether 40 Hz TUS specifically produces these benefits, and whether they extend to individuals without clinical disease, remains conjectural.

Benefit-Modifying Factors

Genetic polymorphisms: APOE4 (apolipoprotein E epsilon-4, a genetic variant that increases Alzheimer’s disease risk) carriers may derive greater benefit given their higher amyloid burden and impaired glymphatic clearance, but no trial has stratified 40 Hz TUS outcomes by APOE genotype. Open-label data from 40 Hz audiovisual stimulation suggest differential responses between early-onset and late-onset Alzheimer’s disease populations, hinting that genetic background matters.
Baseline cognitive status: Clinical trials of 40 Hz stimulation have focused on mild-to-moderate Alzheimer’s disease. Effects in cognitively normal adults remain largely unstudied for 40 Hz TUS. Preclinical studies in wild-type mice show gamma enhancement even in healthy brains, suggesting some benefit may occur regardless of baseline cognition.
Baseline biomarkers: Individuals with elevated plasma p-tau217 (phosphorylated tau at residue 217, a blood biomarker indicating amyloid-related brain changes), positive amyloid-PET (positron emission tomography, an imaging modality that visualizes amyloid plaques in the brain) imaging, or reduced resting gamma-band EEG (electroencephalography, a technique recording scalp electrical activity) power may derive greater benefit because these markers reflect the neurobiological substrates that 40 Hz stimulation is proposed to engage. No trials have yet stratified 40 Hz TUS outcomes by these biomarkers, and the relationship is mechanistic rather than trial-validated.
Sex-based differences: Open-label data from 40 Hz audiovisual stimulation have anecdotally noted strong responses in some female participants with late-onset Alzheimer’s disease, but no sex-stratified data exist for 40 Hz TUS. Skull thickness and density differ modestly between sexes, which could translate into small intensity differences inside the brain.
Pre-existing conditions: Cerebrovascular disease, compromised blood-brain barrier, or active neuroinflammation could alter both ultrasound propagation and glymphatic function, shifting the balance of benefits. Individuals with Lewy body or vascular dementia may respond differently from those with Alzheimer’s disease pathology.
Age: Skull thickness, density, and calcification increase with age, attenuating ultrasound intensity at the brain target. Older individuals may require parameter adjustment to achieve equivalent intracranial pressures. Age-related decline in glymphatic function and aquaporin-4 polarization is also part of the problem the intervention is trying to address, which may shift its risk-benefit profile favorably in this group.

Potential Risks & Side Effects

A dedicated search of the complete side effect profile of transcranial ultrasound stimulation was performed across safety reviews, clinical trial reports, and drug reference sources before writing this section.

Medium 🟥 🟥

Transient Headache

Headache is the most commonly reported side effect across both the transcranial ultrasound literature and the broader 40 Hz gamma stimulation literature. In the audiovisual OVERTURE trial, headache was reported in roughly one-fifth of active participants compared with about one-tenth of sham. In systematic reviews of TUS, reversible headache is the most frequent complaint, usually mild and resolving without intervention.

Magnitude: Reported in approximately 5-22% of participants across studies; typically mild and self-resolving within hours.

Tinnitus (Ringing in the Ears)

Tinnitus (perception of ringing, hissing, or buzzing in the ears without an external sound source) has been reported in audiovisual 40 Hz gamma stimulation trials. The relevance to pure ultrasound stimulation is less clear, since therapeutic frequencies are above the human hearing range, but bone-conducted auditory pathway stimulation from intense pulses remains a theoretical concern and has been reported at high TUS intensities.

Magnitude: Approximately 15% in the audiovisual OVERTURE trial versus near zero in sham; not yet quantified specifically for 40 Hz TUS.

Low 🟥

Nausea and Dizziness

Transient nausea, dizziness, and, more rarely, vomiting have been reported in a small minority of human TUS subjects and typically resolve spontaneously. The mechanism is not fully characterized, but stimulation of vestibular pathways and autonomic centers has been proposed.

Magnitude: Rare, generally under 5% across controlled TUS studies; self-limiting.

Unintended Blood-Brain Barrier Disruption

At intensities and parameter regimes outside those used for neuromodulation, particularly when combined with ultrasound contrast agents, transcranial ultrasound can transiently open the blood-brain barrier. Although this effect is being investigated therapeutically in other contexts, unintended opening could expose brain tissue to circulating proteins and pathogens. Safety reviews have confined such events to studies that intentionally exceeded established safety parameters.

Magnitude: Not observed at the low-intensity parameters used in 40 Hz TUS research; documented only at intentionally higher acoustic exposures.

Microhemorrhage

A small number of studies in the broader TUS safety literature have reported microhemorrhage, again at exposures that exceeded prevailing safety limits. No microhemorrhage has been observed at the parameters used in 40 Hz TUS preclinical studies or in low-intensity human TUS trials conducted within current guidelines.

Magnitude: Not observed at therapeutic intensities; documented only at exposures exceeding FDA safety limits.

Speculative 🟨

Unknown Long-Term Effects

The long-term effects of repeated 40 Hz TUS in humans have not been characterized, because human 40 Hz TUS studies are still short and small. Two-year open-label extension data from 40 Hz audiovisual stimulation have not shown new safety signals, but that does not translate directly to the ultrasound modality.

Seizure Risk from Gamma-Frequency Entrainment

Driving large neuronal populations at gamma frequency in individuals with epilepsy or a lowered seizure threshold could, in principle, provoke seizures. No seizures have been reported across published 40 Hz stimulation studies, but epilepsy has been a standard exclusion criterion and the real-world risk in that population remains untested.

Thermal Effects at High Intensity

Ultrasound energy is partially converted to heat in tissue. The ITRUSST (International Transcranial Ultrasonic Stimulation Safety and Standards) consortium has established that thermal risks are nonsignificant when absolute brain temperature remains under 39 degrees Celsius. Low-intensity protocols remain well below this threshold, but improper device calibration, very long sessions, or malfunctioning equipment could in principle produce clinically meaningful heating.

Risk-Modifying Factors

Genetic polymorphisms: Because 40 Hz TUS is a physical rather than a pharmacological intervention, classical pharmacogenetic variants do not apply. Variants influencing coagulation or vascular integrity (for example factors affecting clotting or small-vessel disease) could influence microhemorrhage risk at the high end of intensity ranges.
Baseline biomarkers: Abnormal coagulation profiles, severe cerebral microangiopathy (disease of the small blood vessels in the brain), or significant cerebral amyloid angiopathy (a condition in which amyloid protein deposits in the walls of small brain blood vessels, increasing bleeding risk) could elevate the risk of microbleeding if parameters are pushed toward upper limits. Baseline brain imaging showing prior microbleeds is a relative concern.
Sex-based differences: No sex-specific adverse event patterns have been identified in TUS studies. Skull thickness varies somewhat between sexes and may influence the intracranial intensity achieved at any given surface dose.
Pre-existing conditions: Individuals with metallic cranial implants, cochlear implants, or ventriculoperitoneal shunts should not undergo TUS due to energy reflection and heating concerns. Uncontrolled epilepsy is a relative contraindication given the theoretical seizure risk. Active intracranial tumors or elevated intracranial pressure warrant avoidance until evaluated by a neurologist.
Age: Older adults often have thicker and more calcified skulls, which attenuate ultrasound and may require higher surface intensities to produce equivalent intracranial stimulation. This narrows the safety margin between therapeutic and potentially harmful doses and makes individualized treatment planning more important.

Key Interactions & Contraindications

Prescription drug interactions: No direct pharmacological interactions exist. Individuals on anticoagulants (blood-thinning medications that reduce clot formation, e.g., warfarin, apixaban, rivaroxaban, dabigatran) may have increased microhemorrhage risk if stimulation parameters are pushed to the high end. Medications that lower seizure threshold (bupropion, tramadol, some antipsychotics (drugs used primarily to treat psychotic disorders such as schizophrenia) and fluoroquinolones) warrant caution given the neural excitability effects of gamma entrainment. Severity: caution; consequence: potential microbleeding or lowered seizure threshold. Mitigation: keep parameters within low-intensity protocols and coordinate with prescribing clinicians.
Over-the-counter medication interactions: NSAIDs (non-steroidal anti-inflammatory drugs, a class including aspirin and ibuprofen that reduce inflammation and can thin the blood) with antiplatelet effects may, in theory, amplify microhemorrhage risk at high acoustic intensities, though no such events have been observed at standard 40 Hz TUS parameters. Severity: caution; consequence: theoretical additive bleeding risk. Mitigation: avoid simultaneous high-dose aspirin with high-intensity protocols.
Supplement interactions: No direct pharmacological interactions. Supplements with anticoagulant or antiplatelet properties, such as high-dose fish oil, vitamin E, and Ginkgo biloba, warrant the same considerations as anticoagulant medications at higher stimulation intensities. Severity: caution; consequence: theoretical additive bleeding risk at high intensities.
Additive supplements: Supplements proposed to support glymphatic function or reduce neuroinflammation (for example, omega-3 fatty acids, curcumin from Curcuma longa, creatine) could theoretically be additive with 40 Hz TUS effects on clearance and microglial phenotype, but no combination trials exist. Severity: monitor; consequence: theoretical additive benefit without established safety risk. Mitigation: maintain standard supplement dosing and track tolerability.
Other intervention interactions: Combining 40 Hz TUS with other neuromodulation techniques (tACS (transcranial alternating current stimulation, which applies small alternating currents via scalp electrodes), rTMS (repetitive transcranial magnetic stimulation, which uses magnetic pulses to stimulate cortical regions), audiovisual 40 Hz stimulation) may produce additive or synergistic effects; combined 40 Hz ultrasound-light protocols have already reported stronger entrainment than either alone. Severity: caution; consequence: unknown combined safety profile. Mitigation: combination protocols should be treated as investigational and monitored independently.
Populations who should avoid this intervention (severity: absolute contraindication; consequence: risk of thermal injury, seizure, microhemorrhage, or unintended blood-brain barrier disruption):
- Individuals with metallic cranial implants, cochlear implants, skull defects, or recent craniotomy (<6 months)
- Individuals with uncontrolled epilepsy or a history of unprovoked seizures
- Pregnant women (precautionary; no human data)
- Individuals with active intracranial tumors, elevated intracranial pressure, or recent intracranial hemorrhage (<90 days)
- Individuals receiving ultrasound contrast agents concurrently
- Individuals with severe, uncontrolled coagulopathy (a bleeding disorder in which the blood’s ability to clot is impaired)

Risk Mitigation Strategies

Adhere to ITRUSST safety parameters: keep mechanical index below 1.9 and intracranial temperature below 39 degrees Celsius, using only devices with documented compliance. This directly addresses the microhemorrhage and thermal-injury risks.
Start at low intensity and titrate slowly: begin at the lowest effective spatial peak pulse average intensity (for example, parameters comparable to published 40 Hz preclinical work, which sit well below FDA safety limits) and increase only if well tolerated, to minimize headache, nausea, and microhemorrhage risk.
Use clinical-grade devices: limit treatment to research-grade systems (NeuroFUS, BrainSonix, NaviFUS) with built-in acoustic output verification rather than unregulated consumer devices marketed as “brain ultrasound”, to reduce the risk of uncharacterized acoustic exposure.
Obtain baseline neuroimaging: a structural MRI (magnetic resonance imaging, a non-invasive scan that produces detailed images of brain structure) before starting can identify contraindications such as metallic implants, vascular malformations, prior microbleeds, and baseline white matter disease, mitigating microhemorrhage and thermal risks.
Screen for seizure history: ask about personal and family history of epilepsy and febrile seizures before starting, to mitigate the theoretical seizure risk from gamma-frequency entrainment. Individuals with such history should receive neurology input first.
Monitor for headache and tinnitus: track frequency and severity of headache and any new tinnitus during the first several weeks, reducing session duration or intensity if persistent, to keep these common side effects at manageable levels.
Operate under clinical supervision: given the investigational status of 40 Hz TUS, treatment should ideally be performed or supervised by a neurologist or neuromodulation specialist with experience in TUS, to catch uncommon adverse events and ensure parameters stay within safety boundaries.

Therapeutic Protocol

40 Hz TUS is an investigational technique without a consensus clinical protocol. The following parameters draw from published preclinical and early clinical research and from the broader low-intensity TUS safety literature; individual protocols should be tailored under expert supervision.

Modality: Low-intensity transcranial focused ultrasound pulsed at a 40 Hz pulse repetition frequency (PRF, the number of ultrasound pulses delivered per second), with a carrier frequency typically between 250 and 650 kHz.
Target: Bilateral hippocampal CA1 region or medial prefrontal cortex for cognitive indications, guided by MRI-based neuronavigation where available.
Intensity: Spatial peak pulse average intensity (Isppa) of approximately 0.5-8 W/cm² (estimated in-vivo transcranial value), with preclinical 40 Hz TUS protocols typically calibrated to produce free-field pressure amplitudes around 0.2 MPa.
Session duration: 1-2 hours per session; preclinical studies have used two-hour sessions, while the audiovisual OVERTURE trial used one-hour sessions.
Treatment course: Daily sessions for at least 2-6 weeks for acute preclinical effects; multi-month durations (for example, six months in OVERTURE and up to two years in the open-label audiovisual extension) have been used in clinical studies of gamma entrainment more broadly.
Best time of day: No optimal timing has been established. Given the link to glymphatic clearance, which peaks during sleep, stimulation earlier in the day or in the hours before sleep has been proposed as complementary, but this has not been tested directly.
Alternative approaches: Audiovisual 40 Hz stimulation, 40 Hz tACS, and combined multimodal protocols represent the main alternatives. Preliminary work has suggested that combining 40 Hz ultrasound with 40 Hz light may produce stronger gamma entrainment than either alone, though combined protocols are still investigational.
Single vs split sessions: Both continuous one- to two-hour daily sessions and split sessions have been explored; the single-session format currently predominates. As a physical modality, “half-life” does not apply; neural after-effects persist for days, and daily sessions produce cumulative benefit.
Genetic polymorphisms: No genotype-specific protocol adjustments have been established. APOE4 carriers may be reasonable candidates for earlier initiation given their elevated risk trajectory, but this is expert opinion rather than trial-based guidance.
Sex-based differences: No sex-specific parameters have been defined. Small differences in skull thickness may warrant individualized intensity calibration by neuronavigation rather than sex-specific defaults.
Age-related considerations: Adults over 60 often have more attenuating skulls; MRI-guided treatment planning can account for individual cranial anatomy to maintain adequate intracranial intensity. Older adults may also stand to benefit most from glymphatic and neuroprotective mechanisms given age-related decline in these systems.
Baseline biomarkers: Individuals with elevated plasma p-tau217 or positive amyloid-PET may be considered priority candidates for treatment based on target-engagement logic, although no biomarker-guided 40 Hz TUS protocol has been validated.
Pre-existing conditions: Mild cognitive impairment and early Alzheimer’s disease are the populations with the most supportive evidence base; vascular or mixed pathology may respond differently and warrant individualized evaluation.

Discontinuation & Cycling

Duration of use: Available evidence supports long-term or indefinite use rather than a defined course. Open-label extensions of 40 Hz audiovisual stimulation have continued daily treatment for up to two years. Preclinical effects on amyloid and gamma power are maintained with ongoing stimulation and may gradually reverse after cessation, with neural effects of single sessions persisting for several days.
Withdrawal effects: No withdrawal syndromes or rebound phenomena have been reported with cessation of 40 Hz stimulation in either preclinical or clinical studies.
Tapering: No tapering protocol is necessary. Treatment can be stopped without gradual reduction.
Cycling: No cycling protocol has been formally studied. Clinical trials have used continuous daily stimulation; whether intermittent schedules (for example, several sessions per week rather than daily) maintain efficacy is an open question.

Sourcing and Quality

40 Hz transcranial ultrasound stimulation equipment falls into two categories: actual TUS systems, which are research or clinical-grade devices, and consumer 40 Hz devices, which are typically audiovisual rather than ultrasound.

Research-grade TUS systems: Only these devices deliver true transcranial focused ultrasound pulsed at 40 Hz. Representative systems include NeuroFUS (Brainbox Ltd), BrainSonix, NaviFUS, and NEUROLITH. None is available for consumer home purchase, and most are restricted to recognized research institutions. 40 Hz TUS currently remains an investigational procedure performed in clinical and research settings.
Consumer 40 Hz audiovisual devices (complementary, not TUS): Examples include the BEACON40 lamp (40 Hz flickering light for home use) and AlzLife (a smartphone app combining 40 Hz light and sound stimulation with cognitive exercises, requiring a display capable of accurately rendering 40 Hz light). Cognito Therapeutics’ Spectris system, designed for clinical use, is still under development as of this writing. These devices should not be conflated with TUS.
Third-party verification: Third-party acoustic calibration, hydrophone verification of output, and independent safety testing are essential for any TUS device. Research-grade systems typically include factory calibration data and periodic recalibration protocols. Consumer audiovisual devices should be evaluated on whether their light and sound outputs can actually be produced at a stable 40 Hz rather than on ultrasound specifications.
Reputable sources: In the research setting, devices are typically obtained directly from manufacturers with institutional agreements. For consumer audiovisual adjuncts, established manufacturers with published specifications and third-party reviews are preferable over generic “gamma wave” or “brain ultrasound” marketing products.

Practical Considerations

Time to effect: Acute neural effects (gamma power increases, microglial activation) occur within a single session in preclinical models. Measurable amyloid-beta reductions typically require roughly two weeks of daily stimulation in mice. In the audiovisual OVERTURE trial, detectable structural changes emerged around three months, with cognitive and functional separation over six months.
Common pitfalls: Conflating consumer 40 Hz audiovisual devices with actual transcranial ultrasound, using unvalidated devices marketed as “brain ultrasound” without verified acoustic parameters, and expecting immediate cognitive improvement from a mechanism that acts over weeks to months are the most frequent errors.
Regulatory status: 40 Hz TUS is investigational and has not been approved by any regulatory agency for routine clinical use. The FDA has not cleared any 40 Hz TUS device for Alzheimer’s disease or cognitive decline. Consumer 40 Hz audiovisual devices are generally marketed as wellness products rather than medical devices.
Cost and accessibility: Research-grade TUS systems cost tens of thousands of dollars and require specialized operator training; access is mostly limited to academic medical centers and trial sites. Consumer 40 Hz audiovisual adjuncts range from free or low-cost apps to several hundred dollars for dedicated lamps and headsets.

Interaction with Foundational Habits

Sleep: 40 Hz stimulation appears to directly engage mechanisms overlapping with sleep-dependent glymphatic clearance, and audiovisual 40 Hz trials have reported reduced sleep fragmentation and longer deep sleep. Direction is potentiating: sessions timed to complement natural overnight clearance may be synergistic, although this specific timing strategy has not been formally tested. Good sleep hygiene is likely to enhance, rather than interfere with, any benefit.
Nutrition: No direct nutritional interactions are known. Indirectly, dietary patterns that support vascular and glymphatic function (for example, Mediterranean-style diets and adequate omega-3 intake) may be complementary; chronic dehydration could reduce cerebrospinal fluid volume and theoretically blunt glymphatic-mediated benefits. Direction: indirect potentiating when vascular and hydration status are good.
Exercise: Aerobic exercise independently increases BDNF (brain-derived neurotrophic factor, a protein supporting neuron survival and growth), supports glymphatic clearance, and can enhance gamma oscillation power. These are mechanistically parallel to 40 Hz stimulation, making the two plausibly additive. Direction: potentiating. No known timing conflicts; stimulation and training sessions can be separated by hours for comfort.
Stress management: Chronic stress and elevated cortisol are associated with hippocampal atrophy and reduced gamma oscillation power, the same substrate that 40 Hz stimulation aims to improve. Low-intensity TUS studies targeting the thalamus and prefrontal cortex have reported anxiolytic effects, suggesting direct plus indirect engagement. Direction: potentiating when stress is reduced; uncontrolled stress is likely to blunt benefits.

Monitoring Protocol & Defining Success

Baseline Labs and Tests

Before initiating 40 Hz TUS (typically in a research or clinical setting) or beginning structured use of 40 Hz audiovisual devices, a baseline assessment is recommended to rule out contraindications, establish reference values, and define individualized goals.

Structural brain MRI to identify contraindications and establish baseline brain volumes
Neuropsychological assessment (for example, MMSE (Mini-Mental State Examination, a brief cognitive screening test) and MoCA (Montreal Cognitive Assessment, a screening test that is more sensitive to mild cognitive impairment))
Plasma p-tau217 and, where available, amyloid-PET to establish baseline amyloid status

Ongoing Monitoring

Ongoing monitoring cadence typically follows: neuropsychological testing every 3-6 months, structural brain MRI every 6-12 months, and plasma p-tau217 every 6-12 months if baseline was elevated.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
MMSE	27-30	Tracks global cognition	Same time of day for consistency; fasting not required
MoCA	26-30	More sensitive to mild impairment	May be used alongside or instead of MMSE
Brain volume (MRI)	Stable or minimal decline (<0.5%/year total brain volume)	Tracks structural neuroprotection	Same scanner and protocol for longitudinal comparability
Plasma p-tau217	Below assay-specific cutoff for amyloid positivity	Tracks amyloid-related pathological change	Emerging biomarker; assays becoming clinically available; fasting not required
EEG gamma power (40 Hz)	Stable or increasing gamma-band power	Confirms neural entrainment and treatment engagement	Research-grade equipment typically required

Qualitative Markers

Cognitive clarity: subjective improvements in word-finding, focus, and working memory
Sleep quality: fewer nighttime awakenings, more restorative sleep, longer deep sleep on consumer wearables
Energy levels: more sustained mental energy across the day
Mood: reduction in anxiety or depressive symptoms and improved emotional regulation

Emerging Research

The field of 40 Hz ultrasound and gamma entrainment is evolving rapidly across several fronts.

Combined ultrasound-light stimulation: Preclinical work (Gao et al., 2026) has reported that dual-modality 40 Hz systems combining ultrasound and visual stimulation produce stronger gamma entrainment and greater amyloid-beta reduction than either modality alone in Alzheimer’s disease model mice. This emerging direction may form the basis of next-generation combination devices.
Frequency optimization: Work comparing different pulse repetition frequencies (Chen et al., 2025) has suggested that non-40 Hz protocols, such as 200 Hz TUS targeting hippocampal CA1, can engage comparable or stronger oscillatory and memory effects than 40 Hz for some cognitive outcomes. This raises the possibility that 40 Hz is not uniquely optimal for every cognitive outcome, an important counterweight to the current enthusiasm for 40 Hz.
Long-term clinical follow-up: Clinical studies (Cimenser et al., 2021) of 40 Hz audiovisual stimulation have reported that daily 1-hour sessions over 6 months were well tolerated, reduced nighttime activity, and preserved daily-living function in mild-to-moderate Alzheimer’s disease patients, with open-label extensions beginning to report multi-year outcomes. Long-term TUS-specific data are still pending.
Active clinical trials: Multiple trials are currently investigating 40 Hz stimulation modalities, including:
- NCT03556280: OVERTURE study of audiovisual gamma stimulation via the GammaSense system in mild-to-moderate Alzheimer’s disease (Cognito Therapeutics; n=60; primary endpoint ADAS-Cog (Alzheimer’s Disease Assessment Scale - Cognitive Subscale, a standard cognitive outcome measure for Alzheimer’s trials) over 6 months; active, not recruiting)
- NCT06829368: Theta-burst transcranial focused ultrasound stimulation to enhance cognition in healthy adults (University of Nottingham; n=20; primary endpoint visual working memory and EEG markers; recruiting)
- NCT07207122: TUS for neurological and cognitive outcomes in neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease (Sanmai Technologies; n=20; primary endpoints include finger tapping, gait, and mood scales; recruiting)
- NCT05904132: Individual closed-loop 40 Hz tACS for Alzheimer’s disease and mild cognitive impairment (Massachusetts General Hospital; n=70; primary endpoints gamma entrainment and cognitive performance; recruiting)
Portable and home-use TUS devices: Research groups are working toward portable, neuronavigation-assisted TUS devices that could, in principle, be used at home under supervision, which would dramatically expand access; current hardware remains institution-bound.
Broader applications and counter-evidence: Beyond neurodegeneration, early human TUS data suggest possible effects in depression, chronic pain, stroke recovery, Parkinson’s disease, and substance use disorders, broadening potential applications. At the same time, null or negative findings in some TUS cognitive enhancement studies and the emergence of alternative frequencies as potentially superior for specific targets are a reminder that 40 Hz is not yet established as the unique optimal protocol.

Conclusion

40 Hz ultrasound is a scientifically interesting but still investigational approach to brain health. The underlying biology is well articulated: gamma rhythm deficits are seen in aging brains and in Alzheimer’s disease, and rhythmic stimulation at this frequency (through light, sound, electrical current, or ultrasound) has been shown in animal work to reduce amyloid burden, enhance the brain’s waste-clearance system, shift microglia toward a protective phenotype, and preserve white matter. Ultrasound has distinctive advantages in that it can reach deep brain structures directly and does not require the person to see or hear the stimulus.

Human evidence for 40 Hz ultrasound specifically is still in its early phase. The more advanced clinical data come from audiovisual gamma stimulation, where six-month trials have shown structural changes and modest cognitive signals, encouraging but not definitive. Much of that clinical program is carried out by organizations with a direct financial stake in the success of 40 Hz gamma stimulation, which is a relevant consideration when weighing the current literature.

For adults oriented toward long-term brain health, the practical landscape is still divided: consumer 40 Hz audiovisual devices are accessible but deliver a different modality, while actual 40 Hz transcranial ultrasound remains within the research and specialist clinical setting. Safety at low intensities looks favorable, and the current evidence shows a biologically coherent mechanism with early but still preliminary human signals.

Top - Benefits - Risks - Protocol

40 Hz Ultrasound for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

Medium 🟩 🟩

Amyloid-Beta Plaque Reduction

Improved Memory and Cognitive Function

Reduced Brain Atrophy and White Matter Preservation

Low 🟩

Enhanced Gamma Power and Neural Synchrony

Microglial Activation and Neuroinflammation Modulation

Glymphatic Clearance Enhancement

Speculative 🟨

Neuroprotection Against Age-Related Cognitive Decline in Cognitively Healthy Adults

Mood and Sleep Improvement

Benefit-Modifying Factors

Potential Risks & Side Effects

Medium 🟥 🟥

Transient Headache

Tinnitus (Ringing in the Ears)

Low 🟥

Nausea and Dizziness

Unintended Blood-Brain Barrier Disruption

Microhemorrhage

Speculative 🟨

Unknown Long-Term Effects

Seizure Risk from Gamma-Frequency Entrainment

Thermal Effects at High Intensity

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Baseline Labs and Tests

Ongoing Monitoring

Qualitative Markers

Emerging Research

Conclusion